




CLERK, U.S. BANKRUPTCY COURT
NORTHERN DISTRICT OF TEXAS

ENTERED

THE DATE OF ENTRY IS ON
THE COURT'S DOCKET

The following constitutes the ruling of the court and has the force and effect therein described.

Signed September 5, 2024


United States Bankruptcy Judge

**IN THE UNITED STATES BANKRUPTCY COURT
FOR THE NORTHERN DISTRICT OF TEXAS
DALLAS DIVISION**

In re:

EIGER BIOPHARMACEUTICALS, *et al.*,¹

Debtors.

Chapter 11
Case No. 24-80040 (SGJ)

(Jointly Administered)

**ORDER (I) AUTHORIZING THE DEBTORS TO REJECT THE MERCK LICENSE
AND (II) GRANTING RELATED RELIEF**

Upon the motion to reject executory contracts under Section 365 of the Bankruptcy Code incorporated into the proposed chapter 11 plan (“Motion”)² of the debtors and debtors in possession in the above-captioned chapter 11 cases (collectively, the “Debtors”), the Debtors seek entry of an order (this “Order”) as set forth in the Plan (a) authorizing the Debtors to reject the Merck License, and (b) granting related relief, each as more fully set forth in the Motion; and this

¹ The Debtors in these chapter 11 cases, together with the last four digits of each Debtor’s federal tax identification number, are: Eiger BioPharmaceuticals, Inc. (1591); EBPI Merger Inc. (9986); EB Pharma LLC (8352); Eiger BioPharmaceuticals Europe Limited (N/A); and EigerBio Europe Limited (N/A). The Debtors’ service address is 2100 Ross Avenue, Dallas, Texas 75201.

² *Fourth Amended Joint Plan of Liquidation of Eiger BioPharmaceuticals, Inc. and its Debtor Affiliates Pursuant to Chapter 11 of the Bankruptcy Code*, Article V. [Dkt. No. 606-1.] (“Plan”) Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to them in the Plan.



Court having jurisdiction over this matter pursuant to 28 U.S.C. § 1334; and this matter being a core proceeding within the meaning of 28 U.S.C. § 157(b)(2); and the Court being able to issue a final order consistent with Article III of the United States Constitution; and venue of this proceeding being proper pursuant to 28 U.S.C. §§ 1408 and 1409; and appropriate notice of and opportunity for a hearing on the Motion having been given; and the relief requested in the Motion being in the best interests of the Debtors' estates, their creditors and other parties in interest; and this Court having found that the Debtors' notice of the Motion and opportunity for a hearing on the Motion were appropriate and that no other notice need be provided; and this Court having reviewed the Motion and having heard the statements in support of the relief requested therein at the Confirmation Hearing before this Court (the "Hearing"); and the Court having determined that the legal and factual bases set forth in the Motion establish just cause for the relief granted herein; and after due deliberation and sufficient cause appearing therefor, it is **HEREBY ORDERED**

THAT:

1. The Motion is GRANTED as set forth herein.
2. Pursuant to Bankruptcy Code section 365, the Merck License is rejected by the Debtors effective immediately upon entry of this Order. The effective time of the rejection of the Merck License shall be governed solely by the terms of this Order notwithstanding any provision of the Plan that otherwise governs the effectiveness of contract rejection thereunder, including the provisions of Article V of the Plan, and without regard to the occurrence or nonoccurrence of the Effective Date or any stay or appeal of the Confirmation Order.
3. This Order is binding on the Debtors and any contract counterparty to the Merck License.

4. Any contract counterparty to the Merck License shall have thirty (30) days from the date of entry of this Order (the “Rejection Damages Bar Date”) to file any claim for damages arising from the rejection of the Merck License. If proofs of claim are not received by KCC on or before the Rejection Damages Bar Date, the holder of the underlying claim shall be barred from asserting such claim against the Debtors and/or receiving distributions from the Debtors on account of such claim in these chapter 11 cases.

5. Nothing herein shall prohibit the Debtors from filing additional motions to reject executory contracts or unexpired leases.

6. Nothing herein shall impair, prejudice, waive, or otherwise affect any rights of the Debtors to object to any claim related to or arising out of the Merck License, including, without limitation, to argue that any claim for damages arising from the rejection of the Merck License is limited to the remedies available under any applicable termination provisions of the Merck License. The Debtors’ right to argue that the Merck License is not an executory contract of the Debtors is specifically reserved.

7. Notice of the Motion as set forth therein shall be deemed good and sufficient notice of such Motion and the requirements of the Bankruptcy Rules, including Bankruptcy Rule 6004(a), and the Bankruptcy Local Rules are satisfied by such notice.

8. Notwithstanding Bankruptcy Rules 6004(h), 7062 or 9014, the terms and conditions of this Order shall be immediately effective and enforceable upon its entry.

9. Notwithstanding the relief granted herein and any actions taken pursuant to such relief, nothing in this Order shall be deemed (a) an admission as to the amount of, basis for, priority, or validity of any claim against a Debtor entity under the Bankruptcy Code or other applicable nonbankruptcy law; (b) a waiver of the Debtors’ or any party in interest’s rights to dispute any

claim or interest on any grounds; (c) a promise or requirement to pay any claim; (d) a waiver of the Debtors' or any other party in interest's rights under the Bankruptcy Code or any other applicable law; (e) an implication or admission that any particular claim is of a type specified or defined in this order or any other order granting the relief requested in this motion or a finding that any particular claim is an administrative expense claim or other priority claim; (f) an approval to assume, adopt, or reject any agreement, contract, program, policy, or lease under section 365 of the Bankruptcy Code; or (g) an admission as to the validity, priority, enforceability, or perfection of any lien on, security interest in, or other encumbrance on property of the Debtors' estates. Any payment made pursuant to this order is not intended to be nor should it be construed as an admission as to the validity of any claim or a waiver of the Debtors' rights to subsequently dispute such claim.

10. The Debtors are authorized to take all such reasonable actions necessary to effectuate the relief granted in this Order in accordance with the Motion.

11. This Court retains exclusive jurisdiction with respect to all matters arising from or related to the implementation, interpretation, and enforcement of this Order.

END OF ORDER

In re:
Eiger BioPharmaceuticals, Inc.
Debtor

Case No. 24-80040-sgj
Chapter 11

CERTIFICATE OF NOTICE

District/off: 0539-8
Date Rcvd: Sep 06, 2024

User: admin
Form ID: pdf012

Page 1 of 5
Total Noticed: 1

The following symbols are used throughout this certificate:

Symbol **Definition**

+ Addresses marked '+' were corrected by inserting the ZIP, adding the last four digits to complete the zip +4, or replacing an incorrect ZIP. USPS regulations require that automation-compatible mail display the correct ZIP.

Notice by first class mail was sent to the following persons/entities by the Bankruptcy Noticing Center on Sep 08, 2024:

Recip ID	Recipient Name and Address
aty	+ Andrew J. Townsell, Sidley Austin LLP, 787 7th Avenue, New York, NY 10019-6088

TOTAL: 1

Notice by electronic transmission was sent to the following persons/entities by the Bankruptcy Noticing Center.
Electronic transmission includes sending notices via email (Email/text and Email/PDF), and electronic data interchange (EDI).

NONE

BYPASSED RECIPIENTS

The following addresses were not sent this bankruptcy notice due to an undeliverable address, *duplicate of an address listed above, *P duplicate of a preferred address, or ## out of date forwarding orders with USPS.

NONE

NOTICE CERTIFICATION

I, Gustava Winters, declare under the penalty of perjury that I have sent the attached document to the above listed entities in the manner shown, and prepared the Certificate of Notice and that it is true and correct to the best of my information and belief.

Meeting of Creditor Notices only (Official Form 309): Pursuant to Fed .R. Bank. P.2002(a)(1), a notice containing the complete Social Security Number (SSN) of the debtor(s) was furnished to all parties listed. This official court copy contains the redacted SSN as required by the bankruptcy rules and the Judiciary's privacy policies.

Date: Sep 08, 2024

Signature: /s/Gustava Winters

CM/ECF NOTICE OF ELECTRONIC FILING

The following persons/entities were sent notice through the court's CM/ECF electronic mail (Email) system on September 5, 2024 at the address(es) listed below:

Name	Email Address
Anne G. Wallace	on behalf of Debtor Eiger BioPharmaceuticals Inc. anne.wallice@sidley.com, anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com
Anne G. Wallace	on behalf of Debtor EBPI Merger Inc. anne.wallice@sidley.com anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com
Anne G. Wallace	on behalf of Jointly Administered Party/Debtor EB Pharma LLC anne.wallice@sidley.com anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com
Anne G. Wallace	on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited anne.wallice@sidley.com anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com
Anne G. Wallace	on behalf of Debtor EB Pharma LLC anne.wallice@sidley.com anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

District/off: 0539-8

User: admin

Page 2 of 5

Date Rcvd: Sep 06, 2024

Form ID: pdf012

Total Noticed: 1

Anne G. Wallace

on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. anne.wallice@sidley.com
anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Anne G. Wallace

on behalf of Debtor Eiger BioPharmaceuticals Europe Limited anne.wallice@sidley.com
anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Anne G. Wallace

on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited anne.wallice@sidley.com
anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Anne G. Wallace

on behalf of Debtor EigerBio Europe Limited anne.wallice@sidley.com
anne--wallice--4789@ecf.pacerpro.com;nyefiling@sidley.com

Beverly Weiss Manne

on behalf of Creditor Thermo Fisher Scientific et al. bmanne@tuckerlaw.com, bewmanne@aol.com

Bruce H White

on behalf of Creditor Dr. Colleen Craig Kaludzinski bwhite@parsonsbehle.com

Candice Marie Carson

on behalf of Creditor Eton Pharmaceuticals Inc. Candice.Carson@butlersnow.com

Charles Martin Persons, Jr.

on behalf of Debtor Eiger BioPharmaceuticals Inc. cpersons@sidley.com,
txefilingnotice@sidley.com;charles-persons-5722@ecf.pacerpro.com

Daniel N. Gonzalez

on behalf of Creditor Committee Official Unsecured Creditors Committee dgonzalez@melandbudwick.com
ltannenbaum@melandbudwick.com;ltannenbaum@ecf.courtdrive.com;mrbnf@yaho.com

David E. Sklar

on behalf of Interested Party Official Equity Security Holders' Committee desklar@pbnlaw.com
mpdermatis@pbnlaw.com;jmoconnor@pbnlaw.com

Dawn Whalen Theiss

on behalf of Creditor United States Of America Internal Revenue Service dawn.theiss@usdoj.gov
brooke.lewis@usdoj.gov;CaseView.ECF@usdoj.gov

Elizabeth Ziegler Young

on behalf of U.S. Trustee United States Trustee elizabeth.a.young@usdoj.gov

Eric M. Van Horn

on behalf of Creditor Merck Sharp & Dohme LLC ericvanhorn@spencerfane.com

Garrick Chase Smith

on behalf of Attorney Munsch Hardt Kopf & Harr P.C. gsmith@munsch.com

Garrick Chase Smith

on behalf of Creditor Committee Official Unsecured Creditors Committee gsmith@munsch.com

Garrick Chase Smith

on behalf of Attorney Meland Budwick P.A. gsmith@munsch.com

George H. Barber

on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP gbarber@bradley.com,
sbyrd@bradley.com;gbarberbradley@ecf.courtdrive.com;george-barber-8068@ecf.pacerpro.com

J. Machir Stull

on behalf of Creditor IQVIA Inc. mstull@jw.com, osalvatierra@jw.com;kgradney@jw.com

Jason S. Brookner

on behalf of Interested Party Eiger InnoTherapeutics Inc. jbrookner@grayreed.com,
lwebb@grayreed.com;acarson@grayreed.com

Jason S. Brookner

on behalf of Creditor Jeffrey S. Glenn Individually jbrookner@grayreed.com, lwebb@grayreed.com;acarson@grayreed.com

Jay Robert Bender

on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP jbender@bradley.com

Jeff P. Prostok

on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP jprostok@forsheyprostok.com,
calendar@forsheyprostok.com;calendar_0573@ecf.courtdrive.com;jprostok@ecf.courtdrive.com;khartogh@forsheyprostok.com;
khartogh@ecf.courtdrive.com;forsheyprostokllp@jubilee.net

John James Sparacino

on behalf of Interested Party Official Equity Security Holders' Committee jsparacino@mckoolsmith.com
john-sparacino-7086@ecf.pacerpro.com;managingclerk@mckoolsmith.com;scastillo@mckoolsmith.com

John Joseph Kuster

District/off: 0539-8
Date Rcvd: Sep 06, 2024

User: admin
Form ID: pdf012

Page 3 of 5
Total Noticed: 1

on behalf of Jointly Administered Party/Debtor EB Pharma LLC jkuster@sidley.com

John Joseph Kuster
on behalf of Interested Party Eiger InnoTherapeutics Inc. jkuster@sidley.com

John Joseph Kuster
on behalf of Debtor Eiger BioPharmaceuticals Inc. jkuster@sidley.com

John Joseph Kuster
on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited jkuster@sidley.com

John Joseph Kuster
on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited jkuster@sidley.com

John Joseph Kuster
on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. jkuster@sidley.com

John Mark Stern
on behalf of Creditor Texas Comptroller of Public Accounts Revenue Accounting Division bk-jstern@oag.texas.gov, sherri.simpson@oag.texas.gov

Joseph R. Dunn
on behalf of Creditor Merck Sharp & Dohme LLC jdunn@cov.com

Kendal B. Reed
on behalf of Creditor Biorasi LLC kreed@condontobin.com, atobin@condontobin.com;cnavarro@condontobin.com;emensch@condontobin.com

Kyle Woodard
on behalf of Creditor Thermo Fisher Scientific et al. kwoodard@krcl.com, KWoodard@ecf.courtdrive.com;ecf@krcl.com

Lawrence James Dickinson
on behalf of Interested Party Sentynl Therapeutics Inc. james.dickinson@pillsburylaw.com, nancy.jones@pillsburylaw.com;docket@pillsburylaw.com

Martin A. Sosland
on behalf of Creditor Eton Pharmaceuticals Inc. martin.sosland@butlersnow.com, ecf.notices@butlersnow.com,velvet.johnson@butlersnow.com

Nathan Elner
on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited nelner@sidley.com

Nathan Elner
on behalf of Debtor EigerBio Europe Limited nelner@sidley.com

Nathan Elner
on behalf of Debtor Eiger BioPharmaceuticals Inc. nelner@sidley.com

Nathan Elner
on behalf of Debtor Eiger BioPharmaceuticals Europe Limited nelner@sidley.com

Nathan Elner
on behalf of Jointly Administered Party/Debtor EB Pharma LLC nelner@sidley.com

Nathan Elner
on behalf of Debtor EB Pharma LLC nelner@sidley.com

Nathan Elner
on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited nelner@sidley.com

Nathan Elner
on behalf of Debtor EBPI Merger Inc. nelner@sidley.com

Nathan Elner
on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. nelner@sidley.com

Patrick J. Neligan, Jr.
on behalf of Debtor Eiger BioPharmaceuticals Inc. pneligan@neliganlaw.com, rclark@neliganlaw.com;jgaiter@neliganlaw.com;cperkins@neliganlaw.com;rclark@ecf.courtdrive.com

Phillip L. Lamberson
on behalf of Creditor Amylyx Pharmaceuticals Inc. plamberson@winstead.com

Roger G. Jones
on behalf of Creditor INNOVATUS LIFE SCIENCES LENDING FUND I LP rjones@bradley.com

S. Margie Venus
on behalf of Interested Party Official Equity Security Holders' Committee mvenus@mckoolsmith.com scastillo@mckoolsmith.com

Shawn M. Christianson
on behalf of Creditor Oracle America Inc. schristianson@buchalter.com, cmcintire@buchalter.com

District/off: 0539-8
Date Rcvd: Sep 06, 2024

User: admin
Form ID: pdf012

Page 4 of 5
Total Noticed: 1

Thomas Daniel Berghman
on behalf of Creditor Committee Official Unsecured Creditors Committee tberghman@munsch.com
amays@munsch.com,CourtMail@munsch.com;hvalentine@munsch.com

Thomas Robert Califano
on behalf of Debtor EBPI Merger Inc. tom.califano@sidley.com
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano
on behalf of Debtor Eiger BioPharmaceuticals Inc. tom.califano@sidley.com,
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano
on behalf of Jointly Administered Party/Debtor EB Pharma LLC tom.califano@sidley.com
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano
on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited tom.califano@sidley.com
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano
on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. tom.califano@sidley.com
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano
on behalf of Debtor Eiger BioPharmaceuticals Europe Limited tom.califano@sidley.com
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano
on behalf of Debtor EB Pharma LLC tom.califano@sidley.com
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano
on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited tom.califano@sidley.com
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Thomas Robert Califano
on behalf of Debtor EigerBio Europe Limited tom.califano@sidley.com
nyefiling@sidley.com;tom-califano-6649@ecf.pacerpro.com;emcdonnell@sidley.com

Trinitee G. Green
on behalf of Creditor Fujifilm Diosynth Biotechnologies U.S.A., Inc. tggreen@polsinelli.com,
docketing@polsinelli.com;robrien@polsinelli.com;bvogt@polsinelli.com

United States Trustee
ustpreion06.da.ecf@usdoj.gov

Veronica A. Courtney
on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. vcourtney@sidley.com
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney
on behalf of Jointly Administered Party/Debtor EB Pharma LLC vcourtney@sidley.com
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney
on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited vcourtney@sidley.com
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney
on behalf of Debtor EB Pharma LLC vcourtney@sidley.com
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney
on behalf of Debtor Eiger BioPharmaceuticals Europe Limited vcourtney@sidley.com
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney
on behalf of Debtor EigerBio Europe Limited vcourtney@sidley.com
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney
on behalf of Debtor EBPI Merger Inc. vcourtney@sidley.com
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney
on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited vcourtney@sidley.com
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

Veronica A. Courtney
on behalf of Debtor Eiger BioPharmaceuticals Inc. vcourtney@sidley.com,
veronica--courtney--6476@ecf.pacerpro.com;txefilingnotice@sidley.com

District/off: 0539-8
Date Rcvd: Sep 06, 2024

User: admin
Form ID: pdf012

Page 5 of 5
Total Noticed: 1

Warren J. Martin, Jr

on behalf of Interested Party Official Equity Security Holders' Committee wjmartin@pbnlaw.com

William E Curtin

on behalf of Debtor EigerBio Europe Limited wcurtin@sidley.com
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Debtor Eiger BioPharmaceuticals Europe Limited wcurtin@sidley.com
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Debtor Eiger BioPharmaceuticals Inc. wcurtin@sidley.com,
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Jointly Administered Party/Debtor EigerBio Europe Limited wcurtin@sidley.com
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Jointly Administered Party/Debtor EB Pharma LLC wcurtin@sidley.com
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Debtor EB Pharma LLC wcurtin@sidley.com william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Jointly Administered Party/Debtor EBPI Merger Inc. wcurtin@sidley.com
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Debtor EBPI Merger Inc. wcurtin@sidley.com william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

William E Curtin

on behalf of Jointly Administered Party/Debtor Eiger BioPharmaceuticals Europe Limited wcurtin@sidley.com
william-curtin-5829@ecf.pacerpro.com;nyefiling@sidley.com

TOTAL: 85